The research and development of new medicines is a lengthy and costly process that can take between 12 and 15 years from initiation to approval by regulatory agencies. Additionally, the majority of drugs resulting from clinical trials never get authorized for commercialization. These discouraging figures have led professionals in the pharmaceutical industry to seek faster and more cost-effective alternatives.
That is why more and more laboratories are embracing the technologies of the fifth industrial revolution, including generative artificial intelligence (AI). According to laboratory experts, the use of AI can significantly shorten the pre-clinical phases before human trials. Traditionally, after the stage of potential molecule discovery, pre-clinical tests are conducted on animals, a process that can take years.
With the use of AI, pharmaceutical companies can streamline this process and save time and costs. A study conducted by analysts from the Boston Consulting Group (BCG) and Wellcome estimates that the use of AI can reduce time and costs by 25% to 50%. However, for this tool to be efficient, providing accurate and reliable data is crucial.
In this regard, companies like Insilico Medicine are leading the way. This organization, along with several pharmaceutical laboratories, has accumulated over 150 drugs in the process of discovery or preclinical development. This figure is significant when compared to the pending projects of the top twenty pharmaceutical companies in the world.
In conclusion, the technology of the fifth industrial revolution, particularly generative AI, is speeding up the discovery of new medicines. This can not only reduce the time and costs involved in drug development but also increase the efficiency in finding solutions for diseases.